1,017 Shares in DaVita Inc. (NYSE:DVA) Acquired by Brooklyn Investment Group

Brooklyn Investment Group acquired a new position in shares of DaVita Inc. (NYSE:DVA) in the third quarter, HoldingsChannel reports. The fund acquired 1,017 shares of the company’s stock, valued at approximately $167,000.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Harvard Management Co. Inc. acquired a new stake in shares of DaVita in the 2nd quarter valued at approximately $55,115,000. FMR LLC raised its position in shares of DaVita by 659.9% during the third quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after purchasing an additional 154,061 shares during the period. Point72 Asset Management L.P. bought a new position in shares of DaVita during the 2nd quarter valued at about $9,615,000. KBC Group NV grew its position in shares of DaVita by 27.3% in the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after purchasing an additional 67,250 shares during the period. Finally, International Assets Investment Management LLC acquired a new stake in DaVita during the 3rd quarter worth approximately $10,346,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Javier Rodriguez sold 9,881 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the transaction, the chief executive officer now directly owns 887,835 shares of the company’s stock, valued at approximately $144,583,929.75. This trade represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. UBS Group boosted their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Bank of America raised their price objective on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. Truist Financial raised their price target on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Finally, Barclays upped their price objective on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $161.80.

DaVita Stock Performance

DVA opened at $165.71 on Thursday. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The business has a 50 day moving average of $158.42 and a 200-day moving average of $148.87. DaVita Inc. has a 12-month low of $98.26 and a 12-month high of $169.51. The stock has a market cap of $13.59 billion, a price-to-earnings ratio of 17.88, a PEG ratio of 0.94 and a beta of 0.89.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). The company had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. DaVita’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.85 earnings per share. On average, equities research analysts expect that DaVita Inc. will post 9.71 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.